A nurse is caring for Ms. Johnson, who has been diagnosed with schizophrenia and recently developed mild catatonia. Which of the following nursing actions is the most appropriate to address her current condition?

B) Provide a calm and quiet environment to reduce sensory overload and agitation.

A) Encourage Ms. Johnson to participate in group activities to promote social interaction.

B) Provide a calm and quiet environment to reduce sensory overload and agitation.

C) Initiate a physical exercise routine to improve her mobility and physical health.

D) Continuously reorient Ms. Johnson to reality to help reduce her delusions.

A nurse is caring for Ms. Johnson, a patient with schizophrenia who has developed catatonia. Considering her current physiological and psychological state, which nursing intervention is the most appropriate to prioritize at this time?

D) Monitoring her vital signs and observing for signs of adverse reactions to antipsychotic medications

A) Initiating a psychoeducation session to help her understand her condition

B) Implementing a hydration protocol to address potential dehydration

C) Engaging her in group therapy sessions to improve social interaction

D) Monitoring her vital signs and observing for signs of adverse reactions to antipsychotic medications

Ms. Johnson is experiencing mild extrapyramidal symptoms (EPS) after starting a low-dose atypical antipsychotic. Which nursing intervention is most appropriate to address her EPS while continuing to manage her psychotic symptoms effectively?

B) Administer an anticholinergic agent as prescribed to alleviate the extrapyramidal symptoms.

A) Discontinue the antipsychotic medication immediately and notify the healthcare provider.

B) Administer an anticholinergic agent as prescribed to alleviate the extrapyramidal symptoms.

C) Increase the dosage of the atypical antipsychotic to enhance symptom control.

D) Suggest switching to a different class of antipsychotic medication.

Ms. Johnson is experiencing mild extrapyramidal symptoms after starting a low-dose atypical antipsychotic. Which nursing intervention is the most appropriate to address these symptoms while maintaining effective management of her psychotic and catatonic features?

C) Introduce an anticholinergic agent to mitigate extrapyramidal symptoms.

A) Increase the dose of the antipsychotic to improve psychotic symptoms.

B) Administer a benzodiazepine to alleviate catatonic symptoms and reassess.

C) Introduce an anticholinergic agent to mitigate extrapyramidal symptoms.

D) Discontinue the antipsychotic and switch to a different class of medication.

Ms. Johnson, a patient with a history of catatonia and extrapyramidal symptoms, has been experiencing mild dizziness potentially related to benzodiazepine use. As the nurse, which of the following interventions should be prioritized to ensure her safety and promote effective medication management?

B) Advise Ms. Johnson to avoid driving or operating heavy machinery until her dizziness resolves.

A) Educate Ms. Johnson about the importance of not abruptly discontinuing benzodiazepine without consulting her healthcare provider.

B) Advise Ms. Johnson to avoid driving or operating heavy machinery until her dizziness resolves.

C) Monitor Ms. Johnson's liver function tests regularly to detect any potential hepatic complications.

D) Collaborate with the pharmacist to adjust the timing of Ms. Johnson's anticholinergic medication to minimize its sedative effects.

Ms. Johnson has been experiencing mild dizziness, possibly related to the benzodiazepine. Which nursing intervention is most appropriate to address this side effect while ensuring her safety and therapeutic adherence?

A) Instruct Ms. Johnson to rise slowly from a sitting or lying position to reduce dizziness.

B) Advise Ms. Johnson to avoid all physical activity until the dizziness subsides.

C) Encourage Ms. Johnson to consume more fluids to counteract the dizziness.

D) Suggest Ms. Johnson take her medication only at night to prevent daytime dizziness.

Ms. Johnson is experiencing increased anxiety and restlessness as her benzodiazepine is being tapered. What is the most appropriate nursing intervention to help manage her anxiety while minimizing potential hepatic complications?

B) Implement a gradual tapering schedule for the benzodiazepine and introduce mindfulness techniques.

A) Increase the dosage of her current benzodiazepine to alleviate anxiety symptoms.

B) Implement a gradual tapering schedule for the benzodiazepine and introduce mindfulness techniques.

C) Administer a higher dose of a different anxiolytic medication with less hepatic metabolism.

D) Suggest discontinuing all medications temporarily to reset her system.

Ms. Johnson's care team observed increased episodes of restlessness and difficulty sleeping, potentially linked to the tapering of her benzodiazepine. Which of the following nursing interventions is most appropriate to address her anxiety symptoms while considering her elevated liver enzymes?

B) Recommend engaging in regular physical exercise to help reduce anxiety levels.

A) Initiate a high-protein diet to support liver function and reduce anxiety.

B) Recommend engaging in regular physical exercise to help reduce anxiety levels.

C) Encourage the use of over-the-counter herbal supplements known for calming effects.

D) Suggest increasing the dosage of her current benzodiazepine to manage anxiety.

A nurse is reviewing the medication regimen of a patient with elevated liver enzymes and psychiatric needs. Which intervention should the nurse prioritize to address the patient's condition?

B) Discuss with the healthcare provider the potential for switching to an antipsychotic with a lower risk of hepatic stress.

A) Continue the current antipsychotic medication and monitor liver enzymes closely.

B) Discuss with the healthcare provider the potential for switching to an antipsychotic with a lower risk of hepatic stress.

C) Administer a higher dose of benzodiazepines to manage anxiety while monitoring liver function.

D) Recommend discontinuation of all psychiatric medications until liver enzymes normalize.

Ms. Johnson's care team has identified a potential drug-induced hepatic complication from her current antipsychotic medication. What is the most appropriate nursing intervention to support liver function while continuing to manage her psychiatric symptoms?

B) Collaborate with the healthcare team to adjust Ms. Johnson's medication to one with a lower hepatic burden.

A) Encourage Ms. Johnson to discontinue all medications immediately to prevent further liver damage.

B) Collaborate with the healthcare team to adjust Ms. Johnson's medication to one with a lower hepatic burden.

C) Focus solely on dietary modifications without altering her medication regimen.

D) Increase the dosage of Ms. Johnson's current antipsychotic to improve psychiatric symptoms regardless of liver function.

acute psychosis from new diagnosis of schizophrenia - Nursing Case Study

Pathophysiology

• Primary mechanism: Dopamine dysregulation - Schizophrenia is associated with hyperactivity of dopamine pathways, particularly in the mesolimbic area, leading to positive symptoms such as hallucinations and delusions. This dysregulation affects neurotransmitter balance, altering perception and thought processes.

• Secondary mechanism: Glutamate dysfunction - Reduced activity of NMDA receptors on glutamate pathways contributes to cognitive deficits and negative symptoms in schizophrenia. This can impair synaptic plasticity and connectivity, crucial for normal cognitive function.

• Key complication: Neurodevelopmental impact - Abnormal brain development, potentially influenced by genetic and environmental factors, leads to structural and functional changes. This can exacerbate symptoms and complicate treatment, highlighting the importance of early intervention.

Patient Profile

Demographics:

32-year-old female, high school teacher

History:

• Key past medical history: No significant medical history; recent family history of mental illness

• Current medications: None

• Allergies: Penicillin

Current Presentation:

• Chief complaint: Hearing voices and experiencing severe paranoia

• Key symptoms: Auditory hallucinations, delusions of persecution, disorganized thinking, agitation, insomnia

• Vital signs: Blood pressure 140/90 mmHg, heart rate 110 bpm, respiratory rate 22 breaths per minute, temperature 37.8°C (100°F)

Section 1

During the initial assessment, further observations revealed that the patient, Ms. Johnson, displayed significant disorganized speech and behavior, consistent with her reported symptoms. Her mental status examination showed marked cognitive disorganization, with an inability to maintain a coherent conversation and frequent derailment of thought processes. She appeared visibly agitated, pacing the room and expressing fears of being followed by unknown entities. Her insight into her condition was poor, as she adamantly believed in the reality of her persecutory delusions. Given her elevated heart rate and blood pressure, the medical team considered her physiological stress response and potential dehydration due to insomnia and agitation.

Lab results returned, indicating mildly elevated white blood cell count at 11,500/mm³, suggestive of a stress response rather than infection, as there were no signs of a physical illness. Thyroid function tests were within normal limits, ruling out hyperthyroidism as a contributing factor to her agitation and tachycardia. A urine toxicology screen was negative, eliminating substance use as a potential cause of her symptoms. Neuroimaging was also conducted to exclude organic causes, which showed no acute intracranial abnormalities but noted slight volumetric reductions in the prefrontal cortex, which can be associated with schizophrenia.

The patient's status evolved with an onset of mild catatonia, characterized by a noticeable reduction in her voluntary movements and a tendency to remain in fixed postures for extended periods. This change prompted the care team to initiate antipsychotic treatment with a low-dose atypical antipsychotic, carefully monitoring for side effects given her sensitivity to medications. The development of catatonia highlighted the complex interplay of neurotransmitter systems and underscored the need for vigilant monitoring and a nuanced approach to pharmacological intervention. As her treatment plan progresses, the team remains focused on stabilizing her acute symptoms while planning for long-term management strategies, emphasizing the importance of psychoeducation and family involvement in her care.

Section 2

The care team closely monitored Ms. Johnson's response to the initiation of the low-dose atypical antipsychotic. Within the first few days, her agitation began to subside slightly, and there was a modest improvement in her ability to engage in brief, structured conversations. However, her catatonic symptoms persisted, with prolonged episodes of immobility and occasional mutism. This prompted the team to reassess her treatment plan, considering the addition of a benzodiazepine to target the catatonia more effectively. Ms. Johnson's vital signs remained stable, with her heart rate gradually normalizing to 85 beats per minute and blood pressure at 130/80 mmHg, indicating a reduction in physiological stress.

Despite these improvements, a new complication emerged as Ms. Johnson began experiencing mild extrapyramidal symptoms, including a subtle tremor in her hands and muscle rigidity. These side effects were likely attributable to the antipsychotic medication, necessitating a careful evaluation of her medication regimen. The team discussed the possibility of adjusting the antipsychotic dosage or introducing an anticholinergic agent to mitigate these symptoms without compromising the management of her psychotic and catatonic features. Concurrently, laboratory tests revealed a slight increase in liver enzymes, with ALT at 60 U/L and AST at 55 U/L, prompting consideration of potential hepatic implications of the medication.

Recognizing the complexity of Ms. Johnson's evolving clinical picture, the interdisciplinary team emphasized the importance of a holistic approach to her care. They coordinated a meeting with her family to discuss the treatment plan, aiming to ensure adherence and support from her social network. Psychoeducation sessions were introduced to help Ms. Johnson and her family understand her diagnosis, the nature of her symptoms, and the expected course of her condition. The team also began exploring long-term management options, including cognitive behavioral therapy and community support services, to promote Ms. Johnson's recovery and reintegration into daily life. This comprehensive strategy aimed not only to stabilize her acute symptoms but also to lay the groundwork for sustained improvement and quality of life.

Section 3

In the weeks following the introduction of the benzodiazepine and adjustments to her antipsychotic regimen, Ms. Johnson demonstrated a mixed response. While her episodes of catatonia diminished, allowing her to engage more consistently in daily activities, the extrapyramidal symptoms persisted, albeit at a manageable level. This prompted the care team to reduce the antipsychotic dosage slightly and introduce a low-dose anticholinergic medication. The addition of the anticholinergic agent resulted in a noticeable reduction in her tremor and muscle rigidity, highlighting the importance of ongoing medication management and monitoring for side effects. However, the slight elevation in liver enzymes remained unchanged, necessitating close surveillance to prevent potential hepatic complications.

Simultaneously, Ms. Johnson's mental status continued to evolve. She became increasingly aware of her surroundings and was able to participate in structured psychoeducation sessions with her family. These sessions not only provided insight into her condition but also empowered her family to create a supportive environment at home. The interdisciplinary team noted that Ms. Johnson's insight into her illness was improving, which is a positive indicator for her long-term prognosis and adherence to treatment. Her vital signs remained stable, although she occasionally reported mild dizziness, possibly related to the benzodiazepine, prompting the team to consider a gradual tapering strategy to minimize sedation risks.

As Ms. Johnson adapted to the therapeutic changes, the team planned to introduce cognitive behavioral therapy (CBT) as a complementary intervention. This decision was based on her increased cognitive engagement and potential for employing coping strategies to manage residual symptoms and stressors. Concurrently, the team worked on connecting Ms. Johnson with community support services to foster social reintegration and enhance her quality of life. These steps were integral to ensuring a comprehensive approach to her recovery, addressing both her psychological and social needs. The team remained vigilant, prepared to adjust her treatment plan as necessary to accommodate any new developments in her clinical status.

Section 4

As Ms. Johnson's treatment progressed, the care team observed a notable change in her status. During a routine follow-up appointment, Ms. Johnson reported experiencing increased episodes of restlessness and difficulty sleeping, despite the initial improvements in her psychotic symptoms. A detailed assessment revealed that her anxiety levels were rising, which could be attributed to the gradual tapering of the benzodiazepine. Her vital signs were stable overall: blood pressure at 120/80 mmHg, heart rate at 78 beats per minute, respiratory rate at 16 breaths per minute, and oxygen saturation at 98% on room air. However, she exhibited mild tachycardia during episodes of heightened anxiety.

Laboratory tests showed a slight increase in her liver enzymes, with ALT rising to 55 U/L and AST to 48 U/L, indicating a potential hepatic response to the ongoing medication regimen. Additionally, her complete blood count revealed a mild leukocytosis with a white blood cell count of 11,500/mm³, necessitating further exploration to rule out any infectious or inflammatory processes. These changes prompted the team to reassess her medication plan, considering a more gradual benzodiazepine taper and evaluating alternatives to manage her anxiety without exacerbating her hepatic function.

In response to these findings, the interdisciplinary team decided to intensify the non-pharmacological components of her treatment. The frequency of cognitive behavioral therapy sessions was increased to help Ms. Johnson develop more effective coping strategies for her anxiety. Additionally, her family was encouraged to engage in supportive family therapy, reinforcing the psychoeducational component and fostering a supportive home environment. The team also closely monitored Ms. Johnson's liver function and anxiety symptoms, ready to adjust her medication regimen as needed to ensure her safety and optimize her recovery trajectory. This proactive approach was crucial in managing her evolving condition and maintaining her progress while minimizing the risk of complications.

Section 5

As the interdisciplinary team continued to monitor Ms. Johnson's condition, a new set of diagnostic results revealed further complications that required immediate attention. Her latest liver function tests showed a continued rise in ALT and AST levels, with ALT now at 72 U/L and AST at 65 U/L, suggesting a worsening hepatic response. These elevations were concerning and prompted a thorough review of her current medication regimen, particularly the antipsychotic medication, which was suspected to be contributing to the hepatic stress. Additionally, her white blood cell count had increased to 12,200/mm³, necessitating a more comprehensive evaluation for potential underlying inflammatory or infectious conditions that could be impacting her overall health and treatment progress.

In light of these findings, Ms. Johnson's care team decided to consult with a hepatologist to determine the most appropriate course of action for managing her liver function while continuing to address her psychiatric needs. The team explored alternative antipsychotic options with a more favorable hepatic profile, aiming to reduce the risk of further liver damage. Additionally, they prioritized enhancing Ms. Johnson's overall treatment plan with lifestyle modifications, such as a liver-friendly diet and increased physical activity, to support her liver health.

The proactive adjustments in her treatment plan resulted in a gradual improvement in Ms. Johnson's laboratory values over the following weeks. Her anxiety symptoms also began to stabilize as the team implemented a slower benzodiazepine taper, complemented by her intensified cognitive behavioral therapy sessions. With the collaborative efforts of her healthcare providers and family, Ms. Johnson demonstrated resilience and adaptability, showing promising signs of recovery as she navigated the complexities of her diagnosis and treatment journey. This period of adjustment underscored the importance of a dynamic and responsive care plan, tailored to address both psychiatric and physiological aspects of her condition, as the team prepared for the next phase of her treatment.